News

The Psychedelic Investor asks: Can DMT Treat Depression?

Can DMT treat depression? James Hallifax, of the Psychedelic Spotlight podcast, sits down to interview Dr. Carol Rutledge, Small Pharma Chief Medical and Science Officer, and discuss the potential of DMT as a mental health drug.

In this 31 minute episode, the Psychedelic Investor asks a number of key questions that Dr. Carol Routledge answers about Small Pharma (TSX.V: DMT, OTC: DMTTF) and current DMT research as an expert in psychedelic medicines with a specialization in DMT.

Can DMT Treat Depression? Jump to any of the questions below:

0:49 What is Small Pharma working on in terms of DMT and Depression?

3:15 Why is Small Pharma focusing on DMT?

5:40: What makes Small Pharma’s proprietary DMT molecule SPL026 different?

7:57 How has DMT been administered in the clinical trials?

8:37 What about DMT duration of effect and SPL028 versus SPL026?

10:17 Is SPL028 the DMT molecule of the future?

11:54 How does DMT-assisted therapy treatment work?

15:03 Do you envision this being a one-off DMT-assisted therapy session or multiple sessions?

16:34 How long lasting might DMT-assisted therapy be?

17:40 How many people are in Phase IIa of the clinical trial?

18:43 How do you create a placebo for DMT?

20:25 Are all the patients in the trial psychedelic naive?

21:01 What happens in the brain that creates a “break-through experience”?

23:30 Have you ever looked into the subjective experiences that people have with DMT?

26:54 Do you think the psychedelic experience is key to DMT-assisted therapy?

30:01 What else can you tell us about Small Pharma?

Small Pharma are focussing on the psychedelic – DMT, which they believe has excellent potential as a mental health drug.

Small Pharma is currently running a Phase IIa Clinical Trial attempting to treat Major Depressive Disorder using DMT, the world’s furthest progress DMT study with patients. Results are expected before the end of the year and dependent on Phase IIa results, the company plans to begin a Phase III Clinical Trial.

About Small Pharma

We’re a mental health drug development company that’s accelerating the development of fast acting antidepressant treatments using DMT based therapies. We’re dedicated to making a difference.

With a focus on innovative approaches and committed to challenging the status quo, we’re targeting the root causes of depression and hoping to unlock the minds of millions.

Get Small Pharma updates

    Investor Deck

    Follow us: